NCT04869683 Biocollection in MyeloDysplastic Syndrome (P-MDS)
| NCT ID | NCT04869683 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Brest |
| Condition | Myelodysplastic Syndromes |
| Study Type | INTERVENTIONAL |
| Enrollment | 150 participants |
| Start Date | 2022-10-19 |
| Primary Completion | 2032-10-19 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 150 participants in total. It began in 2022-10-19 with a primary completion date of 2032-10-19.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Myelodysplastic syndromes (MDS) are chronic myeloid hemopathies characterized by ineffective hematopoiesis (with peripheral cytopenias) and which contrast with a marrow of normal richness. MDS is considered one of the four most common blood diseases. The incidence is estimated at 4,059 cases / year in 2012 with an average age of 78 years in men and 81 years in women (INCA report, Cancers in France in 2015). The incidence increases with lengthening of the lifespan. The main risk of MDS is transformation to acute leukemia in 30 to 40% of cases. Treatment options depend on clinical, hematologic and chromosomal abnormalities. The prognosis is considered to be at low or high risk of developing acute leukemia. This distinction will therefore have an impact on the therapeutic solution (s). MDS exhibit clinical, morphological and genetic heterogeneity. It is therefore necessary to form subgroups of patients to better understand the physiopathogenesis of this pathology. The constitution of a biocollection will make it possible to search for clinical and biological prognostic markers in order to identify patients progressing to acute myeloid leukemia.
Eligibility Criteria
Inclusion Criteria: * Major * patient with or suspected of myelodysplastic syndrome (WHO definition) at diagnosis and/or during follow-up, which is managed at the level of the Cancer-Hematology Institute of the Brest CHRU * Presence of biological material collected within the CRB * Patient's consent obtained Exclusion Criteria : * Minor and pregnant woman * Lack of biological material collected within the CRB * Refusal to participate: lack of consent - Unable to consent * Patient under judicial protection: guardianship, curatorship ...
Contact & Investigator
Nathalie Douet-Guilbert, MD,PhD
PRINCIPAL INVESTIGATOR
CHRU BREST
Frequently Asked Questions
Who can join the NCT04869683 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Myelodysplastic Syndromes. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04869683 currently recruiting?
Yes, NCT04869683 is actively recruiting participants. Contact the research team at nathalie.douet-guilbert@chu-brest.fr for enrollment information.
Where is the NCT04869683 trial being conducted?
This trial is being conducted at Brest, France.
Who is sponsoring the NCT04869683 clinical trial?
NCT04869683 is sponsored by University Hospital, Brest. The principal investigator is Nathalie Douet-Guilbert, MD,PhD at CHRU BREST. The trial plans to enroll 150 participants.